InvestorsObserver
Sign Up Login

EFTR eFFECTOR Therapeutics Inc.

$0.35 $-0.01 (-2.83%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

EFTR Stock Analysis Overview

What this means: InvestorsObserver gives eFFECTOR Therapeutics Inc. (EFTR) an overall rank of 34, which is below average. eFFECTOR Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

EFTR Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

EFTR Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

EFTR Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

EFTR Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

EFTR Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

EFTR Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

EFTR Stock Analysis Overview

What this means: InvestorsObserver gives eFFECTOR Therapeutics Inc. (EFTR) an overall rank of 34, which is below average. eFFECTOR Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full EFTR report

EFTR Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

EFTR Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

EFTR Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

EFTR Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

EFTR Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

EFTR Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

eFFECTOR Therapeutics Inc. (EFTR) Analyst Forecast

EFTR Price, Volume, Earnings, and Dividend Date

  • Last Price $0.35
  • Previous Close $0.36
  • Change $-0.01
  • Open $0.36
  • Volume 164,099
  • Avg. Volume (100-day) 266,819
  • Market Cap 14,831,946
  • Days Range 0.3378 - 0.376
  • 52-week Range 0.35 - 4.3
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 0.8
  • EPS —
  • Earnings Date 05/09/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.776
  • PEG Ratio —

eFFECTOR Therapeutics Inc. (EFTR) Company Description

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

eFFECTOR Therapeutics Inc. (EFTR) Stock Chart

View Interactive EFTR chart

My Watchlists

Top Stocks in Biotechnology